Parathyroid Hormone Market

Parathyroid hormone is a single chain polypeptide made up of 84 amino acids secreted by the parathyroid gland located near the thyroid gland. Inadequate secretion of parathyroid hormone results in the development of diseases related to bone such as osteoporosis, hypocalcaemia, and hyperphosphetemia. Parathyroid hormone controls the distribution of phosphate and calcium in the body. Hypoparathyroidism is a condition, wherein parathyroid glands do not produce sufficient amount of parathyroid hormone (PTH). The disease is characterized by low level of calcium and high levels of phosphate in the blood. According to statistics by Verdict Media Limited., approximately 100,000 people in the U.S. are diagnosed with hyperparathyroidism. 

Increase in incidence and prevalence of conditions related to the imbalance in the parathyroid hormone level in the body due to changing lifestyles, surge in R&D on the development of parathyroid hormone analogues, and improved diagnostic procedures for the detection of parathyroid hormone imbalance are projected to drive the global parathyroid hormone market during the forecast period. In April 2017, Shire plc received approval from the European Commission for Natpar (rhPTH[1-84]). It is the first recombinant human protein with the full length 84-amino acid sequence of endogenous parathyroid hormone (PTH). Moreover, hypoparathyroidism is a rare disease. Hence, the products developed for its treatment are getting orphan drugs designation, leading to increase in research and development in this therapy area. However, complicated process of product development, high cost of manufacturing, and increasingly stringent regulatory requirements are anticipated to restrain the market during the forecast period. 

The global parathyroid hormone market can be segmented based on product type, indication, end-user, and region. In terms of product type, the parathyroid hormone market can be bifurcated into recombinant parathyroid hormones and parathyroid hormone analogues. The parathyroid hormone analogues segment includes teriparatide and abaloparatide. Based on indication, the global parathyroid hormone market can be classified into hypoparathyroidism, osteoporosis, and postmenopausal bone complications. In terms of end-user, the parathyroid hormone market can be divided into hospitals, clinics, and others. The hospitals segment is anticipated to account for major parathyroid hormone market share during the forecast period. However, the clinics segment is likely to expand at the highest CAGR from 2018 to 2026 owing to rise in patient preference for clinics due to improved medical services, cleanliness, and favorable reimbursement scenario.

Based on region, the global parathyroid hormone market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is projected to dominate the global parathyroid hormone market owing to high incidence rate of hypoparathyroidism, increase in health care spending, rise in investment in research related to parathyroid hormone product development by players, and surge in new product approvals in the region. Europe is anticipated to be the second largest market for parathyroid hormone in terms of revenue during the forecast period. Presence of large geriatric population is expected to propel the market in the region. The parathyroid hormone market in Asia Pacific is likely to expand at the highest CAGR due to economy growth and rise in health care expenditure in the developing countries. 

Key players operating in the global parathyroid hormone market include Shire plc, Eli Lilly and Company, Physicians Total Care, Inc., and Radius Health, Inc. Large number of players are participating in the clinical trials of the parathyroid hormone products including Pfizer, Inc. Ascendis Pharma A/S, Entera Bio Ltd., and Extend Biosciences, Inc.